|
84 Companies |
|
139 Products |
|
139 Products |
|
62 Mechanisms of Action |
|
7 Trials |
|
632 News |
|
| «12...234567891011121314» |
- Zolinza (vorinostat) / Merck (MSD), alisertib (MLN8237) / Puma
Enrollment open, Combination therapy, Epigenetic controller: Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma (clinicaltrials.gov) - Apr 23, 2012
P1, N=60, Recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting
- Trial termination: Donor T Cells in Treating Patients With High-Risk Hematologic Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant (clinicaltrials.gov) - Apr 17, 2012
P1, N=3, Terminated, Sponsor: Masonic Cancer Center, University of Minnesota
Not yet recruiting --> Recruiting Active, not recruiting --> Terminated; Slow accrual.
- Enrollment change: Donor T Cells in Treating Patients With High-Risk Hematologic Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant (clinicaltrials.gov) - Apr 17, 2012
P1, N=3, Terminated, Sponsor: Masonic Cancer Center, University of Minnesota
Active, not recruiting --> Terminated; Slow accrual. N=32 --> 3
- Torisel (temsirolimus) / Pfizer
Trial completion: CCI-779 in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Apr 17, 2012
P2, N=89, Completed, Sponsor: National Cancer Institute (NCI)
N=32 --> 3 Terminated --> Completed
- Enrollment closed, Metastases: Laboratory Assay in Determining Cancer Resistance in Patients With Metastatic Cancer and in Healthy Participants (clinicaltrials.gov) - Apr 16, 2012
P=N/A, N=48, Active, not recruiting, Sponsor: Comprehensive Cancer Center of Wake Forest University
Terminated --> Completed Completed --> Active, not recruiting
- deferasirox tablet for oral suspension / Generic mfg.
Enrollment closed: Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies (clinicaltrials.gov) - Apr 15, 2012
P=N/A, N=16, Active, not recruiting, Sponsor: Comprehensive Cancer Center of Wake Forest University
Completed --> Active, not recruiting Recruiting --> Active, not recruiting
- |||| cyclophosphamide / Generic mfg., clofarabine / Generic mfg.
Trial completion: Clofarabine and Cyclophosphamide Combination in Acute Lymphoblastic Leukemia Patients (clinicaltrials.gov) - Apr 15, 2012
P1/2, N=51, Completed, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Bexxar (iodine I 131 tositumomab) / GSK
Trial completion: Long-Term Effects of Iodine I Tositumomab and Autologous Bone Marrow or Stem Cell Transplantation in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Apr 9, 2012
P2, N=36, Completed, Sponsor: Fred Hutchinson Cancer Research Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Neupogen (filgrastim) / Kyowa Kirin, Amgen
Enrollment closed: Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant (clinicaltrials.gov) - Mar 30, 2012
P2, N=88, Active, not recruiting, Sponsor: Cancer and Leukemia Group B
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Zolinza (vorinostat) / Merck (MSD), alisertib (MLN8237) / Puma
New P1 trial, Combination therapy, Epigenetic controller: Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma (clinicaltrials.gov) - Mar 28, 2012
P1, N=60, Recruiting, Sponsor: National Cancer Institute (NCI)
- Elitek (rasburicase) / Sanofi
New P2 trial: Rasburicase and Allopurinol in Treating Patients With Hematologic Malignancies (clinicaltrials.gov) - Mar 25, 2012
P2, N=36, Recruiting, Sponsor: Roswell Park Cancer Institute
- Rituxan (rituximab) / Roche
Trial completion: Rituximab & Combination Chemotherapy Followed by Transplantation in Relapsed or Refractory Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Mar 22, 2012
P2, N=44, Completed, Sponsor: University of Nebraska
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Zolinza (vorinostat) / Merck (MSD), Rituxan (rituximab) / Roche
Enrollment change: Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma (clinicaltrials.gov) - Mar 21, 2012
P1/2, N=29, Active, not recruiting, Sponsor: University of Washington
Active, not recruiting --> Completed N=21 --> 29
- Enrollment closed, HEOR: Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer (clinicaltrials.gov) - Mar 21, 2012
P=N/A, N=80, Active, not recruiting, Sponsor: Comprehensive Cancer Center of Wake Forest University
N=21 --> 29 Recruiting --> Active, not recruiting
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., gemcitabine / Generic mfg.
Trial completion, Combination therapy, Metastases: Combination Chemotherapy in Treating Patients With Recurrent, Refractory, or Metastatic Solid Tumors or Lymphomas (clinicaltrials.gov) - Mar 20, 2012
P1, N=108, Completed, Sponsor: National Institutes of Health Clinical Center (CC)
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Bexxar (iodine I 131 tositumomab) / GSK
Enrollment closed: Iodine I 131 Tositumomab Followed by Autologous Stem Cell Transplantation in Treating Older Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Mar 14, 2012
P2, N=25, Active, not recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Active, not recruiting --> Completed Completed --> Active, not recruiting
- | Trial completion: Umbilical Cord Blood Transplantation in Treating Patients With High-Risk Hematologic Cancer (clinicaltrials.gov) - Mar 13, 2012
P2, N=44, Completed, Sponsor: Case Comprehensive Cancer Center
Completed --> Active, not recruiting Active, not recruiting --> Completed
- Trial completion, HEOR: Caregiver Support in the Quality of Life of Patients Who Are Undergoing Donor Bone Marrow Transplantation (clinicaltrials.gov) - Mar 12, 2012
P=N/A, N=168, Completed, Sponsor: Case Comprehensive Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- melphalan / Generic mfg., busulfan / Generic mfg., thiotepa / Generic mfg.
Enrollment change: Busulfan, Melphalan, and Thiotepa in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Hodgkin's or Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Mar 11, 2012
P2, N=37, Active, not recruiting, Sponsor: OHSU Knight Cancer Institute
Active, not recruiting --> Completed N=30 --> 37
- Trial completion: Fenretinide Lym-X-Sorb (clinicaltrials.gov) - Mar 6, 2012
P1, N=30, Completed, Sponsor: National Institutes of Health Clinical Center (CC)
N=30 --> 37 Active, not recruiting --> Completed
- Trial completion: T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic Malignancies (clinicaltrials.gov) - Mar 6, 2012
P1, N=20, Completed, Sponsor: National Institutes of Health Clinical Center (CC)
Active, not recruiting --> Completed Recruiting --> Completed
- Trial completion: Ravuconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Stem Cell Transplantation (clinicaltrials.gov) - Mar 6, 2012
P1/2, N=0, Completed, Sponsor: National Institutes of Health Clinical Center (CC)
Recruiting --> Completed Active, not recruiting --> Completed
- | Trial completion: Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications (clinicaltrials.gov) - Mar 4, 2012
P3, N=1337, Completed, Sponsor: Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Rituxan (rituximab) / Roche
Trial initiation date: Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant (clinicaltrials.gov) - Mar 1, 2012
P2, N=3, Terminated, Sponsor: Fred Hutchinson Cancer Research Center
Active, not recruiting --> Completed Initiation date: Sep 2011 --> May 2012
- Enrollment change: CRUK-PH1-101: Vaccine Therapy in Treating Patients With Epstein-Barr Virus-Related Cancer (clinicaltrials.gov) - Feb 26, 2012
P1, N=16, Completed, Sponsor: Cancer Research UK
Initiation date: Sep 2011 --> May 2012 N=22 --> 16
- Trial completion: CRUK-PH1-101: Vaccine Therapy in Treating Patients With Epstein-Barr Virus-Related Cancer (clinicaltrials.gov) - Feb 26, 2012
P1, N=16, Completed, Sponsor: Cancer Research UK
N=22 --> 16 Active, not recruiting --> Completed
- Enrollment open: Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies (clinicaltrials.gov) - Feb 23, 2012
P1, N=18, Recruiting, Sponsor: Robert Lowsky
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Enrollment change: Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer (clinicaltrials.gov) - Feb 21, 2012
P2, N=32, Completed, Sponsor: City of Hope Medical Center
Not yet recruiting --> Recruiting N=60 --> 32
- Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Trial completion: Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer (clinicaltrials.gov) - Feb 21, 2012
P2, N=32, Completed, Sponsor: City of Hope Medical Center
N=60 --> 32 Active, not recruiting --> Completed
- fludarabine IV / Generic mfg., busulfan / Generic mfg.
Enrollment closed: Reduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease (clinicaltrials.gov) - Feb 18, 2012
P2, N=70, Active, not recruiting, Sponsor: UNC Lineberger Comprehensive Cancer Center
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Enrollment closed: Fenretinide in Treating Patients With Refractory or Relapsed Hematologic Cancer (clinicaltrials.gov) - Feb 15, 2012
P1, N=40, Active, not recruiting, Sponsor: California Cancer Consortium
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Trial completion: Study of Previously Collected and Stored Tissue Samples From Patients Previously Enrolled in a Completed National Cancer Institute Clinical Trial (clinicaltrials.gov) - Feb 15, 2012
P=N/A, N=241, Completed, Sponsor: National Institutes of Health Clinical Center (CC)
Recruiting --> Active, not recruiting Enrolling by invitation --> Completed
- Trial completion: Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia and Diffuse Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Feb 15, 2012
P2, N=0, Completed, Sponsor: National Institutes of Health Clinical Center (CC)
Enrolling by invitation --> Completed Active, not recruiting --> Completed
- New P1 trial: Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies (clinicaltrials.gov) - Jan 30, 2012
P1, N=18, Recruiting, Sponsor: Robert Lowsky
- peripheral blood stem cell transplantation / National Cancer Institute
Trial completion: A Standardized Nursing Intervention Protocol for HCT Patients (clinicaltrials.gov) - Jan 29, 2012
P=N/A, N=282, Completed, Sponsor: City of Hope Medical Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- cyclophosphamide / Generic mfg., busulfan / Generic mfg.
Enrollment change, Post-transplantation: Combination Chemotherapy, Bone Marrow Transplant, and Post Transplant Cyclophosphamide for Hematologic Cancer (clinicaltrials.gov) - Jan 24, 2012
P2, N=92, Active, not recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Active, not recruiting --> Completed N=60 --> 92
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Enrollment change: Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Leukemia (clinicaltrials.gov) - Jan 24, 2012
P2, N=21, Completed, Sponsor: Sidney Kimmel Comprehensive Cancer Center
N=60 --> 92 N=30 --> 21
- Enrollment change: SWOG-9239 Reduction of Immunosuppression Plus Interferon Alfa and Combination Chemotherapy in Treating Patients With Malignant Tumors That Develop After Organ Transplant (clinicaltrials.gov) - Jan 11, 2012
P2, N=20, Completed, Sponsor: Southwest Oncology Group
N=30 --> 21 N=50 --> 20
- Trial completion: SWOG-9239 Reduction of Immunosuppression Plus Interferon Alfa and Combination Chemotherapy in Treating Patients With Malignant Tumors That Develop After Organ Transplant (clinicaltrials.gov) - Jan 11, 2012
P2, N=20, Completed, Sponsor: Southwest Oncology Group
N=50 --> 20 Active, not recruiting --> Completed
- zidovudine / Generic mfg., trimethoprim/sulfamethoxazole / Generic mfg.
Trial completion: SWOG-9320 Combination Chemotherapy, Radiation Therapy, and Antiviral Therapy in Treating Patients With AIDS-Related Lymphoma (clinicaltrials.gov) - Jan 11, 2012
P2, N=52, Completed, Sponsor: Southwest Oncology Group
Active, not recruiting --> Completed Active, not recruiting --> Completed
- sirolimus / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Clinical: A Pilot Study to Determine the Safety and Tolerability of Sirolimus Given With Hyper-CVAD Chemotherapy (clinicaltrials.gov) - Jan 5, 2012
P=N/A, N=7, Active, not recruiting, Sponsor: Thomas Jefferson University
Active, not recruiting --> Completed N=12 --> 7
- Biomarker: Biomarkers in Samples From Patients With B-Cell Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jan 3, 2012
P=N/A, N=186, Not yet recruiting, Sponsor: Eastern Cooperative Oncology Group
- Decadron (dexamethasone) / Merck (MSD)
Trial completion: Aprepitant in Preventing Nausea and Vomiting in Patients Who Are Undergoing a Stem Cell Transplant (clinicaltrials.gov) - Dec 19, 2011
P=N/A, N=40, Completed, Sponsor: OHSU Knight Cancer Institute
N=12 --> 7 Active, not recruiting --> Completed
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Enrollment closed: Rituximab Combined With Chemotherapy in Burkitt's Lymphoma (clinicaltrials.gov) - Dec 11, 2011
P2, N=20, Active, not recruiting, Sponsor: PETHEMA Foundation
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | alisertib (MLN8237) / Puma
Trial completion: Study of Alisertib (MLN8237) in Adults With Aggressive Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Dec 5, 2011
P2, N=48, Completed, Sponsor: Millennium Pharmaceuticals, Inc.
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- cefepime hydrochloride / Generic mfg.
New P1 trial: Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia (clinicaltrials.gov) - Nov 30, 2011
P1, N=70, Completed, Sponsor: Comprehensive Cancer Center of Wake Forest University
- Rituxan (rituximab) / Roche
Trial termination: Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - Nov 22, 2011
P1/2, N=5, Terminated, Sponsor: Case Comprehensive Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Terminated; Extreme toxicity in Phase I, study did not proceed to Phase II
- Rituxan (rituximab) / Roche
Enrollment change: Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - Nov 22, 2011
P1/2, N=5, Terminated, Sponsor: Case Comprehensive Cancer Center
Active, not recruiting --> Terminated; Extreme toxicity in Phase I, study did not proceed to Phase II N=71 --> 5
- Enrollment open, Metastases: AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma (clinicaltrials.gov) - Nov 6, 2011
P1, N=60, Recruiting, Sponsor: Craig Hofmeister
N=71 --> 5 Not yet recruiting --> Recruiting
- Trial completion: Non-Ablative Allo HSCT For Hematologic Malignancies or SAA (clinicaltrials.gov) - Oct 12, 2011
P2, N=58, Completed, Sponsor: Case Comprehensive Cancer Center
Not yet recruiting --> Recruiting Active, not recruiting --> Completed